Comparison between enzyme-linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS-CoV-2 after symptomatic COVID-19.
Juliette VillemonteixLaure CohenAmélie GuihotValérie GuérinClémentine MoulinMarion CaserisAgnès CarolStéphane BonacorsiGuislaine CarcelainPublished in: Immunity, inflammation and disease (2022)
In patients who recovered from paucisymptomatic COVID-19, the proportion of detectable anti-SARS-CoV-2 responses and their magnitude seemed lower than in patients with more severe symptoms. The ELISpot appeared to be more sensitive than the ICS assay. Short-term culture revealed that paucisymptomatic patients had nonetheless few SARS-CoV-2 T cells at a very low rate in peripheral blood. These data indicate that various ex-vivo assays may lead to different conclusions about the presence or absence of SARS-CoV-2 T cell immunity.
Keyphrases
- sars cov
- high throughput
- flow cytometry
- respiratory syndrome coronavirus
- peripheral blood
- end stage renal disease
- ejection fraction
- newly diagnosed
- single cell
- early onset
- peritoneal dialysis
- prognostic factors
- electronic health record
- depressive symptoms
- reactive oxygen species
- patient reported outcomes
- sleep quality
- artificial intelligence
- patient reported